Business Insider

FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer

SALT LAKE CITY, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that the U.S. Food and Drug Administration ...
The American Journal of Managed Care

Myriad Genetics Submits myChoice HRD as Companion Diagnostic for Niraparib

The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer. Myriad Genetics this week submitted the first part of its application to the FDA ...
News Medical

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...
Business Insider

NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate CancerProlaris®, myRisk® Hereditary Cancer, and myChoice® HRD Testing Are Appropriate For a Total of 200,000 ...

SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for ...
Nasdaq

Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement

Myriad Genetics, Inc. MYGN recently announced the receipt of additional reimbursement in Japan for its myChoice Diagnostic System. Notably, the test aids in identifying patients with advanced ovarian ...
Nasdaq

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

Myriad Genetics, Inc. MYGN recently announced a collaboration with GSK plc GSK to advance in the field of genetic testing. The latest development is intended to improve access to homologous ...